6 days Ago By Defense World Staff
Renaissance Technologies LLC bought a new stake in Stoke Therapeutics, Inc. ( NASDAQ:STOK – Free Report ) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 129,043 shares of the company’s stock, valued at approximately $1,423,000.
Renaissance Technologies LLC owned about 0.24% of Stoke Therapeutics at the end of the most recent quarter. Several other large investors have also recently added to or reduced their stakes in STOK.
KLP Kapitalforvaltning AS acquired a new position in shares of Stoke Therapeutics during the 4th quarter valued at about $63,000. Teacher Retirement System of Texas acquired a new position in Stoke Therapeutics during the fourth quarter worth approximately $113,000. China Universal Asset Management Co.
Ltd. purchased a new position in Stoke Therapeutics during the fourth quarter worth approximately $124,000. Invesco Ltd.
acquired a new position in shares of Stoke Therapeutics in the 4th quarter valued at $133,000. Finally, Wells Fargo & Company MN grew its stake in shares of Stoke Therapeutics by 51.2% during the 4th quarter.
Wells Fargo & Company MN now owns 16,786 shares of the company’s stock valued at $185,000 after buying an additional 5,682 shares during the period. Wall Street Analyst Weigh In STOK has been the topic of several research reports. HC Wainwright reaffirmed a “buy” rating and issued a $47.
00 target price on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Needham & Company LLC restated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, April 9th.
Finally, Chardan Capital reiterated a “buy” rating and set a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock.
According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $24.67.
Stoke Therapeutics Price Performance Shares of NASDAQ STOK opened at $9.47 on Tuesday. Stoke Therapeutics, Inc.
has a 1-year low of $5.35 and a 1-year high of $17.58.
The company has a market capitalization of $517.03 million, a price-to-earnings ratio of -4.51 and a beta of 1.
09. The business has a 50-day moving average of $7.80 and a 200-day moving average of $10.
25. Stoke Therapeutics ( NASDAQ:STOK – Get Free Report ) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.
18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38.
The firm had revenue of $22.61 million during the quarter, compared to analysts’ expectations of $4.20 million.
Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%.
Research analysts expect that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.
Insider Activity at Stoke Therapeutics In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.
67, for a total transaction of $90,011.94. Following the sale, the director now directly owns 148,253 shares in the company, valued at $1,285,353.
51. The trade was a 6.54 % decrease in their position.
The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website . Also, insider Barry Ticho sold 3,884 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.
67, for a total value of $33,674.28. Following the transaction, the insider now owns 63,962 shares of the company’s stock, valued at approximately $554,550.
54. This trade represents a 5.72 % decrease in their ownership of the stock.
The disclosure for this sale can be found here . In the last three months, insiders sold 16,532 shares of company stock valued at $143,332. Corporate insiders own 11.
30% of the company’s stock. Stoke Therapeutics Profile ( Free Report ) Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
Featured Stories Five stocks we like better than Stoke Therapeutics How to Invest in Biotech Stocks Best Defense Stocks in 2025...
So Far Insider Buying Explained: What Investors Need to Know Alphabet Rebounds After Strong Earnings and Buyback Announcement How to Find Undervalued Stocks Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? Want to see what other hedge funds are holding STOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stoke Therapeutics, Inc. ( NASDAQ:STOK – Free Report ).
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
